News

Dutch Agendia raises $65m
Enlarge image

BusinessNetherlands

Dutch Agendia raises $65m

01.06.2012 - Cancer diagnostics specialist Agendia NV closed a $65m private round of equity financing.

Amsterdam – The Dutch company will use the funds to expand commercialisation of their current breast cancer suite of tests, as well as for development of the personalised medicine pipeline, announced CEO David Macdonald. „The support we have received in this round of financing is a strong reflection of our recent growth and confidence in the commercialisation of our product pipeline in the future“, he added.

The financing round was led by the Swiss drug development company Debiopharm Group, with significant support from all of Agendia's current investors, including The Van Herk Group, ING Corporate Investments, Breedinvest and Gilde Healthcare. Korys, the Colruyt family office, was among the new investors.

Agendia's Symphony suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast tumour biology It is currently on the market in the US and Europe and includes several staging, subtyping, recurrence and therapy selection assays. Together, these tests might help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods. „Agendia will support genuine win-win strategies and facilitate the reduction of the gap between the diagnostic and the drug world," said Thierry Mauvernay, Delegate of the Board of Debiopharm.

Agendia was founded in 2003 as a spin-off from The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital in Amsterdam, for the purposes of pursuing commercialisation of molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development.

http://www.european-biotechnology-news.com/news/news/2012-02/dutch-agendia-raises-65m.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOTEC4.06 EUR4.10%
  • VITA 345.72 EUR3.06%
  • SARTORIUS165.00 EUR2.77%

FLOP

  • CYTOS0.65 CHF-4.41%
  • WILEX4.06 EUR-4.02%
  • CO.DON2.80 EUR-3.78%

TOP

  • 4SC4.61 EUR274.8%
  • SYNGENTA422.10 CHF29.1%
  • WILEX4.06 EUR26.9%

FLOP

  • CYTOS0.65 CHF-36.3%
  • MEDIGENE9.02 EUR-31.1%
  • BIOTEST76.17 EUR-22.3%

TOP

  • WILEX4.06 EUR401.2%
  • CYTOS0.65 CHF364.3%
  • 4SC4.61 EUR319.1%

FLOP

  • MOLOGEN4.89 EUR-54.7%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.80 EUR-23.7%

No liability assumed, Date: 21.05.2015